DXR Key Statistics, Chart & Performance
The current stock price of DXR is 13.25 USD. In the past month the price decreased by -2.57%. In the past year, price increased by 37.88%.
DXR Latest News, Press Relases and Analysis
DXR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.49 | 221.37B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.03 | 203.79B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.23 | 145.27B | ||
| SYK | STRYKER CORP | 28.11 | 141.54B | ||
| IDXX | IDEXX LABORATORIES INC | 59.65 | 60.17B | ||
| BDX | BECTON DICKINSON AND CO | 13.24 | 54.73B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.96 | 49.16B | ||
| RMD | RESMED INC | 25.31 | 36.56B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.05 | 35.64B | ||
| DXCM | DEXCOM INC | 33.45 | 24.40B | ||
| PODD | INSULET CORP | 73.86 | 23.75B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.56 | 18.53B |
Related stock screener links
About DXR
Company Profile
Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in New York City, New York. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Company Info
DAXOR CORP
Suite 7120, 350 Fifth Avenue
New York City NEW YORK 10118 US
CEO: Joseph Feldschuh
Employees: 45
Phone: 12122440555
DAXOR CORP / DXR FAQ
Can you describe the business of DAXOR CORP?
Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in New York City, New York. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
What is the stock price of DAXOR CORP today?
The current stock price of DXR is 13.25 USD. The price increased by 0.43% in the last trading session.
What is the dividend status of DAXOR CORP?
DXR does not pay a dividend.
What is the ChartMill technical and fundamental rating of DXR stock?
DXR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for DAXOR CORP?
DAXOR CORP (DXR) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Should I buy DXR stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DXR.
Can you provide the market cap for DAXOR CORP?
DAXOR CORP (DXR) has a market capitalization of 65.98M USD. This makes DXR a Micro Cap stock.
DXR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DXR. When comparing the yearly performance of all stocks, DXR is one of the better performing stocks in the market, outperforming 90.2% of all stocks.
DXR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DXR. The financial health of DXR is average, but there are quite some concerns on its profitability.
DXR Financial Highlights
Over the last trailing twelve months DXR reported a non-GAAP Earnings per Share(EPS) of 0.41. The EPS increased by 22.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2707.08% | ||
| ROA | 5.01% | ||
| ROE | 5.05% | ||
| Debt/Equity | 0.01 |
DXR Forecast & Estimates
5 analysts have analysed DXR and the average price target is 23.97 USD. This implies a price increase of 80.91% is expected in the next year compared to the current price of 13.25.